Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study.
Takeshita E, Ishibashi K, Koda K, Oda N, Yoshimatsu K, Sato Y, Oya M, Yamaguchi S, Nakajima H, Momma T, Maekawa H, Tsubaki M, Yamada T, Kobayashi M, Tanakaya K, Ishida H. Takeshita E, et al. Among authors: nakajima h. Surg Today. 2021 Aug;51(8):1309-1319. doi: 10.1007/s00595-021-02230-8. Epub 2021 Feb 14. Surg Today. 2021. PMID: 33586034
A Japanese multicenter phase II study of adjuvant chemotherapy with mFOLFOX6/CAPOX for stage III colon cancer treatment after D2/D3 lymphadenectomy.
Yoshimatsu K, Ishibashi K, Koda K, Yokomizo H, Oda N, Oshiro M, Kato H, Oya M, Nakajima H, Ooki S, Maekawa H, Matsunami T, Tsubaki M, Yamada T, Kobayashi M, Tanakaya K, Yokoyama M, Ishida H. Yoshimatsu K, et al. Among authors: nakajima h. Surg Today. 2019 Jun;49(6):498-506. doi: 10.1007/s00595-019-1771-y. Epub 2019 Apr 5. Surg Today. 2019. PMID: 30953164 Clinical Trial.
Oxaliplatin-induced increase in splenic volume: experiences from multicenter study in Japan.
Ohta R, Yamada T, Hara K, Iwai T, Tanakaya K, Ishibashi K, Yoshimatsu K, Kosugi C, Tsubaki M, Nakajima H, Oya M, Yoshida H, Koda K, Ishida H. Ohta R, et al. Among authors: nakajima h. Int J Clin Oncol. 2020 Dec;25(12):2075-2082. doi: 10.1007/s10147-020-01763-1. Epub 2020 Aug 12. Int J Clin Oncol. 2020. PMID: 32785799 Clinical Trial.
Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.
Fukushima T, Nakamura T, Iwao H, Nakajima A, Miki M, Sato T, Sakai T, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Nakajima H, Motoo Y, Umehara H. Fukushima T, et al. Among authors: nakajima h, nakajima a. Anticancer Res. 2011 Jun;31(6):2297-302. Anticancer Res. 2011. PMID: 21737655
Measuring body composition using the bioelectrical impedance method can predict the outcomes of gemcitabine-based chemotherapy in patients with pancreatobiliary tract cancer.
Muramatsu M, Tsuchiya A, Ohta S, Iijima Y, Maruyama M, Onodera Y, Hagihara M, Nakaya N, Sato I, Omura K, Ueno S, Nakajima H. Muramatsu M, et al. Among authors: nakajima h. Oncol Lett. 2015 Dec;10(6):3535-3541. doi: 10.3892/ol.2015.3811. Epub 2015 Oct 16. Oncol Lett. 2015. PMID: 26788165 Free PMC article.
Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine.
Shimasaki T, Ishigaki Y, Nakamura Y, Takata T, Nakaya N, Nakajima H, Sato I, Zhao X, Kitano A, Kawakami K, Tanaka T, Takegami T, Tomosugi N, Minamoto T, Motoo Y. Shimasaki T, et al. Among authors: nakajima h. J Gastroenterol. 2012 Mar;47(3):321-33. doi: 10.1007/s00535-011-0484-9. Epub 2011 Nov 1. J Gastroenterol. 2012. PMID: 22041920
4,305 results